344 Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial

• Nathan Bahary,
• Sylvie Rottey,
• Wells Messersmith,
• Zhou Zhu,
• Jordi Rodon,
• Wael Harb,
• Daniel Weng Tan,
• Ignacio Garrido Laguna,
• J Thaddeus Beck,
• Shibing Deng,
• Karen Kowalski,
• Grainne O’Neill,
• Caimiao Wei,
• Nuzhat Pathan

Affiliations

Nathan Bahary

Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Sylvie Rottey

Aff3 0000 0004 0626 3303grid.410566.0Drug Research Unit GhentGhent University Hospital Ghent Belgium

Wells Messersmith

1University of Colorado School of Medicin, Aurora, CO, USA

Zhou Zhu

1 Department of Neurology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

Jordi Rodon

1MD Anderson Cancer Center, Houston, TX, USA

Wael Harb

2Horizon Oncology Center, Lafayette, IN, USA

Daniel Weng Tan

2National Cancer Centre Singapore, Singapore

Ignacio Garrido Laguna

3University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, USA, Salt Lake City, UT, USA

J Thaddeus Beck

5Highlands Oncology Group, Fayetteville, Arkansas, USA, Fayetteville, AR, USA

Shibing Deng

8Pfizer, San Diego, California, USA, San Diego, CA, USA

Karen Kowalski

8Pfizer, San Diego, California, USA, San Diego, CA, USA

Grainne O’Neill

9Pfizer, Walton Oaks, Surrey, UK, Walton Oaks, UK

Caimiao Wei

10Pfizer, Groton, Connecticut, USA, Groton, CT, USA

Nuzhat Pathan

8Pfizer, San Diego, California, USA, San Diego, CA, USA